Leader in Biomolecular Solutions for Life Science

Recombinant SARS-CoV-2 Envelope Protein



Catalog No.: RP01263LQ Recombinant 9 Publications

Sequence Information

Species Gene ID **Swiss Prot**

<I>E. 43740570

coli</l>

Tags N-His&Avi

Synonyms

2019-nCoV E protein;2019-nCoV sM protein; Envelope protein; Env polyprotein;Envelope glycoprotein;env;COVID-19;E

Product Information

Source

Purification

> 95% by SDS-PAGE.

Endotoxin

< 0.1 EU/µg of the protein by LAL method.

Formulation

Supplied as a 0.22 µm filtered solution in 20mM Tris,250mM NaCl, 0.5%TritonX-100, pH 8.0. Contact us for customized product form or formulation.

Reconstitution

Background

Basic Information

Description

Recombinant SARS-CoV-2(2019-nCoV) Envelope Protein is produced by <I>E. coli</I> expression system. The target protein is expressed with sequence (Met1-Val75) of SARS-COV-2(2019-nCoV) Envelope (Accession #QHD43418.1) fused with an initial Met,a 6×His,Avi tag at the N-terminus.

Bio-Activity

Measured by its binding ability in a functional ELISA. Immobilized Recombinant SARS-CoV-2 Envelope at 2 µg/mL (100 µL/well) can bind Recombinant SARS-CoV-2 Nucleocapsid with a linear range of 1.2-41.1 ng/mL.

This product is stable at \leq -70°C for up to 6 months from the date of receipt.
For optimal storage, aliquot into smaller quantities after centrifugation and store at recommended temperature.


Avoid repeated freeze/thaw cycles.

Contact




www.abclonal.com

Validation Data



Recombinant SARS-CoV-2 Envelope Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 12 kDa.



Immobilized Recombinant SARS-CoV-2 Envelope at 2 μ g/mL (100 μ L/well) can bind Recombinant SARS-CoV-2 Nucleocapsid with a linear range of 1.2-41.1 ng/mL.